-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Basal cell carcinoma (BCC) is a common cancer in the world.
In the past, researchers used molecular data of human basal cell carcinoma to screen for drug location and determined that histone deacetylase (HDAC) inhibitors are a potential treatment for basal cell carcinoma
This is an open-label, single-center Phase II trial that recruits patients with basal cell carcinoma
Change in tumor diameter at the 8th week
Change in tumor diameter at the 8th week33 tumors from 25 patients were included in the analysis
The overall response rate was 69.
Pathological changes before and after treatment
Pathological changes before and after treatmentPharmacodynamic analysis showed that the level of acetylated histone H3 in the skin tissues before and after treatment was similar, but the phosphorylation level was increased
All in all, the HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce the disease burden of basal cell carcinoma
The HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce the disease burden of basal cell carcinoma.
Original source:
James M.
Phase II Open-Label, Single- Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma
in this message